Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib
Open Access
- 1 August 2009
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 4 (8), 994-1001
- https://doi.org/10.1097/jto.0b013e3181a94a2f
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely definedAnnals Of Oncology, 2008
- Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?Journal of Clinical Oncology, 2008
- Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase IIIJournal of Clinical Oncology, 2008
- End Points in Advanced Colon Cancer Clinical Trials: A Review and ProposalJournal of Clinical Oncology, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2004
- Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)British Journal of Cancer, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLCJournal of Clinical Oncology, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003